Modified and stabilized GDF propeptides and uses thereof

Details Modified and stabilized GDF propeptides and uses thereof Modified and stabilized GDF propeptides and uses thereof

2007-04-10

2007-04-10

Allen, Marianne P. (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C435S006120, C435S069400, C435S320100, C435S325000, C530S399000

Reexamination Certificate

active

10071499

ABSTRACT:
Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the modified propeptides to prevent or treat human or animal disorders in which an increase in muscle tissue would be therapeutically beneficial. Such disorders include muscle or neuromuscular disorders (such as amyotrophic lateral sclerosis, muscular dystrophy, muscle atrophy, congestive obstructive pulmonary disease, muscle wasting syndrome, sarcopenia, or cachexia), metabolic diseases or disorders (such as such as type 2 diabetes, noninsulin-dependent diabetes mellitus, hyperglycemia, or obesity), adipose tissue disorders (such as obesity), and bone degenerative diseases (such as osteoporosis).

REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 5116944 (1992-05-01), Sivam et al.
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5639638 (1997-06-01), Wozney et al.
patent: 5700911 (1997-12-01), Wozney et al.
patent: 5723125 (1998-03-01), Chang et al.
patent: 5756457 (1998-05-01), Wang et al.
patent: 5827733 (1998-10-01), Lee et al.
patent: 5914234 (1999-06-01), Lee et al.
patent: 5994618 (1999-11-01), Lee et al.
patent: 6004937 (1999-12-01), Wood et al.
patent: 6096506 (2000-08-01), Lee et al.
patent: 6340668 (2002-01-01), Celeste et al.
patent: 6368597 (2002-04-01), Strassmann et al.
patent: 6369201 (2002-04-01), Barker et al.
patent: 6437111 (2002-08-01), Wozney et al.
patent: 6656475 (2003-12-01), Lee et al.
patent: 6696260 (2004-02-01), Lee et al.
patent: 6835544 (2004-12-01), Mathews et al.
patent: 2002/0150577 (2002-10-01), Lee et al.
patent: 2003/0138422 (2003-07-01), Aghajanian et al.
patent: 2003/0162714 (2003-08-01), Hill et al.
patent: 2003/0180306 (2003-09-01), Hill et al.
patent: 2004/0077053 (2004-04-01), Lee et al.
patent: 2004/0138118 (2004-07-01), Wolfman et al.
patent: 2004/0142382 (2004-07-01), Veldman et al.
patent: 2004/0181033 (2004-09-01), Han et al.
patent: 2004/0223966 (2004-11-01), Wolfman et al.
patent: 2005/0043232 (2005-02-01), Lee et al.
patent: 1 061 940 (2003-12-01), None
patent: 1 444 985 (2004-08-01), None
patent: WO 94-21681 (1994-09-01), None
patent: WO 94-26892 (1994-11-01), None
patent: WO 96-01845 (1996-01-01), None
patent: WO 99/24058 (1999-05-01), None
patent: WO 99/45949 (1999-09-01), None
patent: WO 99/56768 (1999-11-01), None
patent: WO 00/11163 (2000-03-01), None
patent: WO 00/43781 (2000-07-01), None
patent: WO 01-64888 (2001-09-01), None
patent: WO 02/09641 (2002-02-01), None
patent: WO 03-027248 (2003-04-01), None
patent: WO 2004/058988 (2004-07-01), None
Thies et al. “GDF-8 Propeptide Binds to GDF-8 and Antagonizes Biological Activity by Inhibiting GDF-8 Receptor Binding” Growth Factors, 18:251-259 (Nov./Dec. 2001)—Correction of citation from 1449 filed on Jun. 24, 2005.
Zwijsen et al., “Characterization of a Rat C6 Glioma-Secreted Follistatin-Related Protein (FRP) Cloning and Sequence of the Human Homologue” Eur J. Biochem. 225: 937-946 (1994)—Correction of citation from 1449 filed on Jun. 24, 2005.
Bowie et al, 1990, Science 247:1306-1310.
Wells, 1990, Biochemistry 29:8509-8517.
Skolnick et al. 2000, Trends in Biotech. 18:34-39.
Bork . 2000, Genome Research 10:398-400.
Doerks et al. 1998, Trends in Genetics 14:248-250.
Vukicevic et al. 1996, PNAS USA 93:9021-9026.
Massague, 1987, Cell 49:437-8.
Pilbeam et al., 1993, Bone 14:717-720.
Partial International Search Report for International Application No. PCT/US02/03467, mailed Dec. 6, 2002.
Hamrick et al., “Bone Mineral Content and Density in the Humerus of Adult Myostatin-Deficient Mice”Calcified Tissue International, 71(1):63-68 (2002).
Lee et al., “Regulation of Myostatin Activity and Muscle Growth”PNAS, 98(16):9306-9311 (2001).
Zhu et al., “Dominant Negative Myostatin Produces Hypertrophy Without Hyperplasia in Muscle”FEBS Letters, 474:71-75 (2000).
McPherron et al. “Double Muscling in Cattle Due to Mutations in the Myostatin Gene”PNAS, 94:12457-12461 (Nov. 1997).
Thies et al. “GDF-8 Propeptide Binds to GDF-8 and Antagonizes Biological Activity by Inhibiting GDF-8 Receptor Binding”Growth Factors, 18:251-259 (2000).
Jiang, et al., “Characterization and Identification of the Inhibitory Domain of GDF-8 Propeptide,”Biochem. Biophys. Res. 315:525-531 (2004).
Alexander et al., “Human Parathyroid Hormone 1-34 Reverses Bone Loss In Ovariectomized Mice,”J. Bone Miner. Res. 16:1665-1673 (2001).
Alliel et al., “Testican, a Multidomain Testicular Proteoglycan Resembling Modulators of Cell Social Behaviour,”Eur. J. Biochem. 214:347-350 (1993).
Amthor et al., “The Expression and Regulation of Follistatin and a Follistatin-like Gene During Avian Somite Compartmentalization and Myogenesis,”Dev. Biol. 178:343-362 (1996).
Andersson et al., “RepeatedIn VivoDeterminations of Bone Mineral Density During Parathyroid Hormone Treatment in Ovariectomized Mice,”J. Endocrinol. 170:529-537 (2001).
Ashmore et al., “Comparative Aspects of Muscle Fiber Types in Fetuses of the Normal and “Double-Muscled” Cattle,”Growth38:501-506 (1974).
Attisano et al., “Activation of Signalling by the Activin Receptor Complex,”Mol. Cell. Biol. 16:1066-1073 (1996).
Bakker et al., Duchenne and Becker Muscular Dystrophies. InDiagnostic Criteria for Neuromuscular Disorders, 2nd ed., Emery, ed., Royal Society of Medicine Press, 1998; pp. 1-4.
Bartholin et al., “FLRG, an Activin-Binding Protein, is a New Target of TGFβ Transcription Activation Through Smad Proteins,”Oncogene20:5409-5419 (2001).
Blader et al., “Cleavage of the BMP-4 Antagonist Chordin by Zebrafish Tolloid,”Science278:1937-1940 (1997).
Bogdanovich et al., “Functional Improvement of Dystrophic Muscle by Myostatin Blockade,”Nature 420:418-421 (2002).
Brown et al., “Physicochemical Activation of Recombinant Latent Transforming Growth Factor-beta's 1, 2, and 3,”Growth Factors3:35-43 (1990).
Bulfield et al., “X Chromosome-Linked Muscular Dystrophy (mdx) in the Mouse,”Proc. Natl. Acad. Sci. U.S.A. 81:1189-1192 (1984).
D'Angelo et al., “Authentic Matrix Vesicles Contain Active Metalloproteases (MMP),”J. Biol. Chem. 276:11347-11353 (2001).
Derynck et al., “Human Transforming Growth Factor-β Complementary DNA Sequence and Expression in Normal and Transformed Cells,”Nature316:701-705 (1985).
Donoghue et al., “Rostrocaudal Gradient of Transgene Expression in Adult Skeletal Muscle,”Proc. Natl. Acad. Sci. U.S.A. 88:5846-5851 (1991).
Emery, “The Muscular Dystrophies,”Lancet359:687-695 (2002).
Escolar et al., “Pharmacologic and Genetic Therapy for Childhood Muscular Dystrophies,”Current Neurology and Neuroscience Reports1:168-174 (2001).
Gamer et al., “A Novel BMP Expressed in Developing Mouse Limb, Spinal Cord, and Tail Bud Is a Potent Mesoderm Inducer inXenopusEmbryos,”Dev. Biol. 208:222-232 (1999).
Gamer et al., “Gdf11 is a Negative Regulator of Chondrogenesis and Myogenesis in the Developing Chick Limb,”Dev. Biol. 229:407-420 (2001).
Gentry et al., “The Pro Domain of Pre-Pro-Transforming Growth Factor β1 When Independently Expressed is a Functional Binding Protein for the Mature Growth Factor,”Biochemistry29:6851-6857 (1990).
Gillis, “Multivariate Evaluation of the Functional Recovery Obtained by the Overexpression of Utrophin in Skeletal Muscles of themdxMouse,”Neuromuscular Disorders12:S90-S94 (2002).
Gonzalez-Cadavid et al., “Organization of the Human Myostatin Gene and Expression in Healthy Men and HIV-Infected Men With Muscle Wasting,”Proc. Natl. Acad. Sci. U.S.A.95:14938-14943 (1998).
Grady et al., “Skeletal and Cardiac Myopathies in Mice Lacking Utrophin and Dystrophin: A Model for Duchenne Muscular Dystropy,

Affiliated with

Also associated with

Rating

Modified and stabilized GDF propeptides and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modified and stabilized GDF propeptides and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified and stabilized GDF propeptides and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3739485